Thuy Tran MD PhD

Melanoma

Assistant Professor of Medicine (Medical Oncology)

35 Park StNew Haven, CT 06510
Phone+1 203-200-6622
Fax+1 203-937-3803

Dr. Tran is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Tran's full profile Already have an account?

Education & Training

Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2015 - 2019
Yale-New Haven Medical CenterResidency, Internal Medicine, 2013 - 2015
Vanderbilt University School of MedicineClass of 2013

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CT State Medical License 2015 - 2027
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Biotech Accelerator Award The Blavatnik Fund for Innovation at Yale, 2023
Stephen A. Sherwin ’70 MD Translational Research Fellowship Award 2023

Clinical Trials

An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) Start of enrollment: 2019 Jul 18
ACTIVE_NOT_RECRUITING
PHASE2
XTX202 in Patients With Advanced Solid Tumors Start of enrollment: 2022 Jan 18
COMPLETED
PHASE1, PHASE2
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001) Start of enrollment: 2023 Jul 19
ACTIVE_NOT_RECRUITING
PHASE3

Publications & Presentations

PubMed

Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study.
Adnan Khattak, Matteo S Carlino, Tarek Meniawy, George Ansstas, Matthew H Taylor
Journal of Clinical Oncology. 2026-06-01
1 citations
Targeting an essential viral oncoprotein with an IL-7-enhanced mRNA vaccine induces durable immunity to Merkel cell carcinoma.
Alexander Frey, Kathryn Clulo, Yuewei Fei, Therese Cordero Dumit, Frankie Scallo
Cell Reports. 2025-10-28
4 citations
Improving immunotherapy responses by dual inhibition of macrophage migration inhibitory factor and PD-1.
Thuy T Tran, Gabriela Athziri Sánchez-Zuno, Lais Osmani, Jasmine Caulfield, Caroline Naomi Valdez
JCI Insight. 2025-10-22

Press Mentions

Improving Immunotherapy Responses by Approaching on Two FrontsOctober 22nd, 2025
Defying the Odds: A WWII Veteran’s Journey with MelanomaMay 22nd, 2025
Yale Study Highlights Unmet Needs for Patients with Melanoma Who Progress or Relapse After Immunotherapy TreatmentAugust 30th, 2024